Mild-to-moderate AD patients were randomized to placebo or rosiglitazone (RSG) 2, 4 or 8 mg. Primary end points at Week 24 were mean change from baseline in AD Assessment Scale-Cognitive (ADAS-Cog) and Clinician's Interview-Based Impression of Change Plus Caregiver Input global scores in the intention-to-treat population (N ¼ 511), and results were also stratified by apolipoprotein E (APOE) genotype (n ¼ 323). No statistically significant differences on primary end points were detected between placebo and any RSG dose. There was a significant interaction between APOE e4 allele status and ADAS-Cog (P ¼ 0.014). Exploratory analyses demonstrated significant improvement in ADAS-Cog in APOE e4-negative patients on 8 mg RSG (P ¼ 0.024; not corrected for multiplicity). APOE e4-positive patients did not show improvement and showed a decline at the lowest RSG dose (P ¼ 0.012; not corrected for multiplicity). Exploratory analyses suggested that APOE e4 non-carriers exhibited cognitive and functional improvement in response to RSG, whereas APOE e4 allele carriers showed no improvement and some decline was noted. These preliminary findings require confirmation in appropriate clinical studies.
Introduction
Alzheimer's disease (AD) is a progressive neurodegenerative disorder characterized by multiple cognitive deficits including worsening of memory, judgment, and comprehension and deterioration in global functioning. It is estimated that the prevalence of AD currently exceeds 18 million worldwide, and is expected to increase significantly with the increasing elderly population. 1 Acetylcholinesterase (AChE) inhibitors, widely approved for mild-to-moderate AD, are not efficacious in every patient, and lose efficacy over time. New therapies are needed to satisfy unmet medical need in AD.
Genetic studies have demonstrated a robust association of the e4 allele of the apolipoprotein E (APOE) gene and late-onset familial and sporadic AD. 2, 3 Three common alleles designated e2, e3 and e4 have allele frequencies of 0.07, 0.78 and 0.15, respectively, in the general Caucasian population, and have a major effect on the risk for AD. The APOE e4 allele is associated with an increased risk and earlier age-at-onset, with e4/e4 homozygotes having the greatest risk and earliest age-at-onset. 4 One or two copies of the APOE e4 allele are present in approximately 40-50% of AD patients. The APOE e2 allele confers a decreased risk and older age-at-onset; the e3 allele has intermediate effects. 5 In patients with clinical AD, there are regionally specific areas of the brain with diminished glucose utilization. [5] [6] [7] Regionally specific altered glucose metabolism can be detected decades before the predicted age of onset of clinical symptoms in APOE e4-positive individuals, who are more susceptible to an earlier onset of AD. 6, 8 The central nervous system (CNS) uses glucose as its primary fuel, and the main pathway for glucose oxidation is the tricarboxylic acid (TCA) cycle. Declines in key brain mitochondrial TCA enzymatic activities in AD patients have been well documented and associated with APOE e4 status. 9, 10 Insulin is critically important in peripheral and central energy metabolism and serves to regulate blood glucose levels. Insulin is transported across the blood/brain barrier and peripheral levels of insulin tend to correlate with levels in the CNS. 11 Insulin has involvement in normal memory function and disorders in peripheral insulin metabolism, such as insulin resistance and hyperinsulinemia, may have a negative influence on memory, as well as increase the risk of developing AD. [12] [13] [14] Peroxisome proliferator-activated receptor g (PPARg) mediates the transcriptional enhancement of a number of genes encoding proteins that regulate lipid metabolism, suggesting a pivotal role in the adipogenic signaling cascade and lipid homeostasis. 15 Rosiglitazone (RSG), a PPARg agonist and an approved antidiabetic pharmacotherapy, is an insulinsensitizing agent that allows the body to use endogenous insulin more efficiently, maintain normal physiological feedback mechanisms 16, 17 and produce anti-inflammatory actions. 18 A positive cognitive effect has been observed in a small pilot study of RSG in AD patients. 19 A strong biological rationale exists to test RSG's efficacy in AD.
For these reasons, we conducted a trial of efficacy and tolerability of RSG as monotherapy in patients with mildto-moderate AD.
Results

Study population
Six hundred eighty-seven patients were screened between January 6, 2004 and May 30, 2005 , at 67 centers in Europe and New Zealand, and 518 patients were randomly assigned to study groups with 511 of these in the intention-to-treat (ITT) population. Sixty-nine patients discontinued treatment before Week 24, and 18 patients for adverse events, which were distributed evenly across treatment groups. The remaining 449 completed the study (Figure 1 ).
The baseline characteristics and AD histories were similar across treatment groups (Table 1) ; approximately two-thirds were female; mean age of 70 years; mean baseline MiniMental State Examination (MMSE) score was 21. Baseline fasting plasma insulin values were mildly elevated (85.2 pM, n ¼ 511). When these values were stratified by APOE e4 status, e4-negative patients had higher values (83 pM, n ¼ 179) than e4-positive patients (n ¼ 73 pM, n ¼ 140).
Efficacy
The results for the primary end points are shown in Table 2 and Figure 2 . The treatment effect of RSG as measured by change from baseline in AD Assessment Scale-Cognitive (ADAS-Cog) at Week 24 was not statistically different from that of placebo. As conditions were not met to proceed with hierarchical testing, further ITT results, including Clinician's Interview-Based Impression of Change Plus 
APOE and efficacy measures
Genotyping results were obtained for a total of 322 subjects of the 511 included in the main statistical analysis for the study and allele frequencies are summarized in Table 3 . Treatment regimens were allocated before genotyping. The demographics of the ITT pharmacogenetic population were similar to the entire study population (mean age 70. A breakdown of the change in ADAS-Cog at the end of the 24-week study by APOE allelic status and treatment regimen is shown in Figure 3 and 4. A prospectively defined test for interaction between APOE e4 carriage status and treatment, as predictors of ADAS-Cog total score change from baseline to Week 24, was significant (P ¼ 0.014) ( Table 2) . Subsequent exploratory testing revealed that APOE e4-negative patients, after 24 weeks, showed improvement in cognitive function as a result of treatment with RSG that was significant at the highest dosage, 8 mg, compared to placebo (P ¼ 0.024, not adjusted for multiplicity) ( Figure 3 ). APOE e4-positive patients showed no improvement; the group receiving 2 mg RSG exhibited a decline (P ¼ 0.012, not adjusted for multiplicity), whereas the 4 and 8 mg dose groups show little change from placebo-treated APOE e4-positive patients ( Figure 3 ).
To explore the potential decline in APOE e4-positive patients, the change in ADAS-Cog total scores from baseline to Week 24 in individual e4 heterozygotes and homozygotes was plotted ( Figure 4 ). The plot suggests that e4 homozygotes declined more than heterozygotes, consistent with a possible dose effect of e4 allele number. Similar results, including a significant interaction between APOE e4 carriage status and treatment (Po0.007), were noted when data were analyzed by observed case (completer) analysis.
A similar pattern of results was identified using the Disability Assessment of Dementia (DAD) test. A prospectively The potential impact of insulin resistance on these observations was tested. There was a significant interaction (P ¼ 0.023) between treatment and APOE e4 allelic status for change from baseline in Week 24 fasting plasma insulin. The mean change from baseline (90% confidence interval (CI)) in fasting insulin levels in APOE e4-negative patients was À11.11 pmol/l (À32.23, 10.01), À23.09 pmol/l (À44.48, À1.70) and À43.75 pmol/l (À65.23, À22.28) in RSG 2, 4 and 8 mg treatment groups, respectively. The mean change from baseline (90% CI) in fasting insulin levels in APOE e4-positive patients was À12.02 pmol/l (À35.37, 11.34), 27.93 pmol/l (4.63, 51.22) and À26.04 pmol/l (À49.16, À2.92) in RSG 2, 4 and 8 mg treatment groups, respectively. Safety and tolerability RSG was generally well tolerated. Adverse events were reported in 35% of patients in the placebo-treated group, 28% of 2 mg group, 31% of 4 mg group and 34% of 8 mg group. Incidence of treatment-emergent adverse events is shown in Table 4 . No unexpected dose-related adverse events were seen. A small number of cases of edema were seen in RSG-treated patients, and none were seen on placebo. The number of subjects with serious adverse events (SAEs) during the study is placebo (7/124 ¼ 6% of subjects); A prospectively defined test for interaction between APOE e4 carriage status and treatment, as predictors of ADAS-Cog total score change from baseline to week 24 was significant (P ¼ 0.014). 2 mg RSG (6/128 ¼ 5%); 4 mg RSG (3/131 ¼ 2%, including one fatality owing to acute cardiac failure unrelated to study drug); and 8 mg RSG (9/135 ¼ 7%). With the exception of one report of atrial fibrillation and cardiac failure in a single subject (RSG 8 mg), other SAEs were not considered to be related to the study medication. Subsequent analyses did not demonstrate any difference in the number or type of adverse events and APOE allele status.
Discussion
In our study, RSG 2, 4 and 8 mg daily had no statistically significant treatment effect on cognition as measured by ADAS-Cog in the ITT population. However, prospectively defined tests for interaction between treatment and APOE e4 allelic status were significant for ADAS-Cog. This interaction was primarily the result of unexplained improvement at Week 24 in APOE e4-positive patients receiving placebo. However, there was also an indication of an interaction at Week 16 before this improvement at Week 24 was observed (P ¼ 0.12). The study was initially powered to detect an effect of APOE e4 allelic status on both ADAS-Cog and CIBIC-Plus; Figure 3 ADAS-Cog scores in APOE e4-negative vs APOE e4-positive cohorts. Analysis of interaction between APOE carriage status and ADASCog change from baseline to Week 24 was significant (P ¼ 0.014). Subsequent exploratory testing revealed that APOE e4-negative patients, after 24 weeks, showed an improvement that was statistically significant at the highest rosiglitazone dose (8 mg) compared to placebo (P ¼ 0.024, not adjusted for multiplicity). APOE e4-positive patients do not show an improvement in cognition but rather showed a decline at rosiglitazone 2 mg (P ¼ 0.012; not adjusted for multiplicity). Figure 4 Individual ADAS-Cog scores in patients with APOE e4/e4 and APOE e4/x genotypes. Rosiglitazone-treated e4 homozygotes had ADASCog scores that overlapped completely those of e4 heterozygotes. Individual points proportional to number of subjects with same change in score.
however, a relatively low pharmacogenetic sampling rate (63%) potentially limited the statistical evaluation of CIBIC-Plus. Exploratory analyses showed improvement (À2.9 points) of cognition in APOE e4-negative patients treated with 8 mg RSG at Week 24; currently available AChE inhibitors have demonstrated improvements ranging between À0.84 to À3.99 points. [20] [21] [22] In contrast, there was no cognitive improvement in APOE e4-positive patients and a decline ( þ 3.6 points) in the group receiving 2 mg RSG. It is possible that e4 homozygotes contributed to this decline or that the decline represents typical progression of AD in a subgroup of patients not benefited by RSG. However, these interpretations are uncertain because of the small number of e4 homozygotes (n ¼ 4-12); moreover, there was no dose-response relationship in the decline.
Early reports in relatively small cohorts with AD suggested that the AChE inhibitors tacrine 23 and donepezil 24 showed increased efficacy in APOE e4-negative or -positive patients, respectively. However, studies in larger AD cohorts have not replicated these findings. 25 Together, these results support observations that defects in cerebral glucose metabolism may underlie the pathology of AD and insulin sensitizers (in this case, RSG) may stabilize or improve the clinical course of the disease. 6 APOE e4 is a well-demonstrated susceptibility factor for AD, 2, 3 and FDG-PET scans of AD patients have demonstrated diminished glucose metabolism. 6 These disturbances in cerebral glucose metabolism antedate clinical symptoms by decades in e4-positive patients. 6 Furthermore, insulin resistance is implicated as an AD risk factor 26, 27 and there are links between hyperinsulinemia, AD and APOE e4.
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In fact, we observed a mild elevation in baseline plasma insulin values in this ITT population, which may indicate the presence of insulin resistance. However, the apparent interaction we observed was difficult to interpret owing to an inverted response in the 4 mg RSG APOE e4-positive treatment group and will be investigated in future studies.
The role of APOE e4 in the pathogenesis leading to greater susceptibility and earlier age-at-onset for AD has not been determined. However, mitochondrial dysfunction in AD appears to vary by APOE genotype, with greater dysfunction in APOE e4 carriers. 10 There is significant evidence that degradation fragments of the apoE4 protein have a greater neurotoxic effect on mitochondrial function over time compared to apoE3 or apoE2 fragments. [28] [29] [30] [31] These fragments, found in cultured neuronal cells and AD brain, induce neurofibrillary tangle-like structures and cause neurotoxicity in vitro. 28, 31 When expressed in transgenic mice, the fragments cause neurodegeneration and behavioral deficits. 30 One hypothesis is that apoE fragments escape from the secretory pathway and enter the cytoplasm, where the lipid-binding region of the fragment mediates interactions with the mitochondria. 28 ApoE4 is more susceptible to degradation owing to protein folding differences between the isoforms. 18, 30, 31 At a mechanistic level, the relationship between APOE, RSG and cognition has not been elucidated. Several lines of evidence support a direct role of PPARg agonists, including RSG, on mitochondrial metabolism and remodeling. With regard to brain tissue, Dello Russo et al. 32 demonstrated that PPARg agonists increased glucose metabolism in astrocytes and modified astrocyte metabolism and mitochondrial function. Mitochondrial biogenesis and elevated energy expenditure have been observed in white adipocytes treated with RSG, suggesting that enhanced lipid utilization in this tissue may affect whole model energy homeostasis and insulin sensitivity. 33 Mitochondrial remodeling and elevated energy expenditure were observed in murine white adipocytes treated with RSG, suggesting that enhanced lipid utilization in this tissue may affect whole model energy homeostasis and insulin sensitivity. 34 Finally, RSG promoted cell survival and enhanced mitochondrial potential in Table 4 Most frequent treatment emergent adverse events
Efficacy of rosiglitazone in a genetically defined population ME Risner et al human peripheral T-lymphocytes. 35 Together, these findings support the hypothesis that RSG is increasing efficiency and the number of brain mitochondria, thereby increasing glucose utilization and improving cognition in AD patients.
It is interesting to speculate why APOE e4-positive patients may not have responded to RSG as well as APOE e4-negative patients. As described above, toxic degradation fragments of apoE4 can damage mitochondria in the CNS, 29 thereby diminishing mitochondrial participation in glycolytic processes, which are sub-served by insulin and insulin sensitizers. APOE e4-positive patients have decreased cerebral glucose metabolism for many years before clinical onset of AD symptoms. 6 These patients may have sustained excessive mitochondrial toxicity and therefore may not experience maximal benefit from RSG when they are diagnosed with AD.
The statistical difference observed in the APOE e4-positive group receiving 2 mg RSG (Figure 1b) was primarily owing to the unexplained improvement observed in the placebo group, with a particularly large improvement (420 points) in several patients. However, patients receiving 2 mg RSG were observed to decline at a rate similar to untreated AD cohorts, [20] [21] [22] demonstrating no treatment effect. In this scenario, APOE e4-positive patients receiving 4 or 8 mg RSG may show a dose-dependent improvement over 2 mg RSG. This interpretation would be compatible with the hypothesis that patients carrying the APOE e4 allele may require a higher dose for a therapeutic response than patients who do not carry an APOE e4 allele. Only further clinical trials will distinguish between these alternative explanations.
The APOE-dependent effects of RSG require confirmation in additional trials that are powered to distinguish genotype-specific responses; they are too preliminary to apply to clinical practice. It can be hypothesized that e2/e3 patients would have the best response followed by e3/e3Xe2/e44e3/ e44e4/e4 patients. If confirmed, these findings will support a potential new treatment for patients with AD, in whom efficacy is both pharmacogenetically defined and predicted. Other trials could determine if RSG slows or prevents AD symptoms in pre-symptomatic APOE-e4 carriers with a predictable rate of AD onset, between the ages of 60 and 70 years. These examples illustrate strategies using genetic data for drug development and the possibility of achieving disease prevention.
Materials and methods
Study subjects
The study recruited patients between 50 and 85 years old with a clinical diagnosis of probable AD in accordance with National Institute of Neurological and Communicative Disorders and Stroke-Alzheimer's Disease and Related Disorders Association (NINCDS-ADRDA) criteria 36 of mild-tomoderate severity, as defined by an MMSE 37 score of 16-26 inclusive at screening. Patients were screened to exclude dementia secondary to causes other than AD. A computed tomography (CT) scan or magnetic resonance imaging scan performed within the past 12 months had to show no evidence of tumor, other structural abnormality or degenerative disease other than AD. All patients resided with (or had regular substantial periods of contact with) a permanent caregiver who was willing to attend all visits and oversee the subject's compliance. Patients with possible, probable or definite vascular dementia in accordance with the National Institute of Neurological Disorders and Stroke-Association Internationale pour la Recherche et l'Enseignement en Neurosciences (NINDS-AIREN) criteria 38 and patients with depression (score on Hospital Anxiety and Depression Scale (HADS) depression questions 47) or any other clinically significant coexisting medical or laboratory abnormalities were also excluded.
Concurrent or recent treatments (within 3 months before the beginning of the study) were not permitted for the following: cholinesterase inhibitors, selegiline, memantine, thiazolidinediones, PPARg agonists, insulin; or treatment for congestive heart failure (including but not limited to beta-blockers, ACE inhibitors, angiotensin II antagonists, nitrates, diuretics, and spironolactone). Use of other treatments significantly affecting cognition and/or behavior (e.g. antipsychotics, sedatives, hypnotics) was not permitted during the study or within 30 days before study enrollment.
Key patient exclusion criteria were history of Type I or Type II diabetes mellitus, a fasting blood glucose level 47.0 mmol/l or hemoglobin A1c (HbA1c) 46.2% and New York Heart Association cardiac status classes 2, 3 or 4.
Study design
In this 24-week, double-blind, parallel-group study, patients were randomly assigned 1:1:1:1 to receive RSG (2, 4 and 8 mg/once daily in an unmarketed formulation) or an identical placebo. A permuted block randomization was used to avoid long strings of one treatment group and sites remained blinded to treatment allocation.
Sixty-seven centers in Europe and New Zealand participated. The study was conducted in accordance with the principles of Good Clinical Practice and the 1996 Declaration of Helsinki. The protocol and its amendments were reviewed and approved by an ethics committee for each participating site. Written informed consent was obtained from patients if capable, or from their legal representative.
Safety evaluations conducted throughout the study included physical examinations, vital sign measurements and standard laboratory tests (blood chemistry including lipid profile, HbA1C, fasting glucose, liver function tests and hematology). Adverse events were recorded at each visit through the study.
GlaxoSmithKline provided the funding and study drug and conducted the study. GlaxoSmithKline designed the protocol with the assistance of external consultants, and conducted the data analysis and interpretation. The data are stored at GlaxoSmithKline.
Efficacy of rosiglitazone in a genetically defined population ME Risner et al
Efficacy variables
The two pre-specified primary end points were change from baseline to Week 24 in the ADAS-Cog 39 and the CIBIC-Plus 40 global score at 24 weeks. Secondary end points included the DAD 41 and NPI. 42 Additional efficacy measures included markers of glycemic control, lipid parameters and inflammation.
APOE genotyping Additional separate informed consent was obtained for genetic sampling, and consent to genetic testing was not a requirement for enrollment. APOE genotyping was performed as previously described by MacLeod et al. 43 
Statistical analysis
The primary analysis was conducted according to the ITT principle and included all patients randomized who had at least one post-dose assessment. The study was powered at 90% to show a 0.5 point difference on CIBIC-Plus at the 0.05 level of significance (n ¼ 106/cohort), and at 95% to show a 3.0 point difference on ADAS-Cog at the 0.05 level of significance for the overall population. An analysis of covariance model was used including terms for treatment, baseline value (for ADAS-Cog only), country, screening MMSE and screening body mass index. Potential covariates were pre-defined in the analysis plan and kept in the model if shown to have a significant effect. For comparison with earlier studies, last observation carried forward was used to impute for missing values. A hierarchical test procedure was used to control type I error. The ADAS-Cog was tested first looking at an overall treatment effect. If the effect was significant at the 5% level, then dose response was to be investigated. If at least one dose of RSG was found to be significantly different from placebo for ADAS-Cog, then a similar testing procedure was to be followed for CIBIC-Plus. Other secondary end points were submitted to exploratory analyses where the P-values were not adjusted for multiple comparisons.
Regardless of hierarchical testing outcome, ADAS-Cog and CIBIC-Plus were to be tested prospectively for interaction with APOE e4 carriage status. Analysis of covariance was again used including the same covariates as described above but also including the main effect for APOE e4 carriage status and the treatment by APOE e4 carriage status interaction. Given that only the test for main effect of treatment was powered in the full population, the significance level for the interaction was taken as Pp0.1. The primary analysis for APOE e4 allelic status was also conducted according to the ITT principle and included all patients randomized and consented. The primary measures were as described above, but summarized by APOE genotype, APOE e4 copies and APOE e4 carriage. If treatment interaction of efficacy measures with APOE e4 allelic status were statistically significant, subsequent exploratory comparisons were made at the 5% level of significance with no adjustment for multiple testing.
